Arbutus Biopharma Corp: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 4, 2023 and accepted by EDGAR at May 4, 2023, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $6.7m | us-gaap:Revenues |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $18.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$17.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $198.0k | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$16.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | −$0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 161,643,404 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | −$27.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $117.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $40.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $152.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $191.2m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $25.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $47.3m | us-gaap:Liabilities |
| Long-term debt | At period end2023-03-31 | $0 | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2023-03-31 | $143.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001447028-23-000025. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.